Freenome Raises $270M in Series C

Freenome has successfully raised $270M in a Series C at a $1.1B valuation led by T. Rowe Price, Perceptive Advisors.

Company Overview

Freenome is a Biotech company headquartered in South San Francisco, CA, founded in 2014 with 300+ employees.

Early cancer detection using AI

Fundraising Details

- Amount Raised: $270M
- Round Type: Series C
- Valuation: $1.1B
- Date: 2021-02-09
- Investors: T. Rowe Price, Perceptive Advisors

About Freenome

Early cancer detection using AI The company is positioned in the Biotech sector, serving a growing market with innovative solutions.

Key Information

- Headquarters: South San Francisco, CA
- Founded: 2014
- Team Size: 300+
- Industry: Biotech

What This Means

This funding round demonstrates strong investor confidence in Freenome's vision and execution. The capital will likely be used to:

- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Freenome's successful fundraising reflects the strong fundamentals and growth potential in this space.

Valuation Milestone

Reaching a $1.1B valuation marks an important milestone for Freenome, positioning the company among notable players in the Biotech industry.

Looking Ahead

With this new capital, Freenome is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

---

This fundraising news was reported on 2021-02-09. For more information about Freenome, visit their headquarters at South San Francisco, CA.